In Q2 fiscal 2026 (the quarter ended June 30, 2026), Stryker's largest business segment was MedSurg and Neurotechnology, with $3.63 billion or 55% of revenue, up 9.7% from a year earlier. Next: Orthopaedics (45%).
By product or service, Orthopaedics brought in 45%, Medical brought in 17% and Endoscopy brought in 15% of revenue in Q2 fiscal 2026.
By region, United States brought in 75% and Non-US brought in 25% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was MedSurg and Neurotechnology (+9.7%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Fiscal quarters, from company filings
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| MedSurg and Neurotechnology | $3.6B | $3.2B | $3.8B | $3.3B | 55% |
| Orthopaedics | $3.0B | $2.8B | $2.3B | $2.7B | 45% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Orthopaedics | $3.0B | $2.8B | $2.3B | $2.7B | 45% |
| Medical | $1.1B | $902.0M | $985.0M | $990.0M | 17% |
| Endoscopy | $1.0B | $868.0M | $896.0M | $899.0M | 15% |
| Instruments | $1.0B | $920.0M | $760.0M | $918.0M | 15% |
| Neurovascular | $496.0M | $517.0M | $525.0M | $498.0M | 8% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $5.0B | $4.5B | $4.6B | $4.6B | 75% |
| Non-US | $1.6B | $1.5B | $1.5B | $1.5B | 25% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
MedSurg and Neurotechnology and Orthopaedics (as reported for Q2 fiscal 2026).
MedSurg and Neurotechnology: $3.63 billion, or 55% of revenue, in Q2 fiscal 2026.
By revenue in Q2 fiscal 2026: Orthopaedics (45%), Medical (17%), Endoscopy (15%) and Instruments (15%).
By region in Q2 fiscal 2026: United States (75%) and Non-US (25%).
Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i
Fiscal quarter ended Jun 30, 2026
| Item | Revenue | Share |
|---|---|---|
| MedSurg and Neurotechnology | USD 3.63B | 55.0% |
| Orthopaedics | USD 2.96B | 45.0% |
Sum of items USD 6.59B. Shares are of the items shown. Click an item with › to see its parts.
Every item and period in one grid. Purple = calculated; "–" = not available.
| Item | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 | Q4 FY23 | Q3 FY23 | Q2 FY23 | Q1 FY23 | Q4 FY22 | Q3 FY22 | Q2 FY22 | Q1 FY22 | Q4 FY21 | Q3 FY21 | Q2 FY21 | Q1 FY21 | Q4 FY20 | Q3 FY20 | Q2 FY20 | Q1 FY20 | Q4 FY19 | Q3 FY19 | Q2 FY19 | Q1 FY19 | Q4 FY18 | Q3 FY18 | Q2 FY18 | Q1 FY18 | Q4 FY17 | Q3 FY17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology | 3.6B | 3.2B | 4.6B | 3.8B | 3.3B | 3.1B | 3.9B | 3.3B | 3.2B | 3.1B | 3.8B | 2.9B | 2.9B | 2.7B | 3.3B | 2.6B | 2.5B | 2.4B | 2.6B | 2.3B | 2.4B | 2.2B | – | 1.6B | 1.3B | 1.6B | – | 1.6B | 1.6B | 1.5B | 1.7B | 1.4B | 1.5B | 1.4B | – | 1.3B |
| Orthopaedics | 3.0B | 2.8B | 2.6B | 2.3B | 2.7B | 2.8B | 2.6B | 2.2B | 2.2B | 2.1B | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.3B | 894.0M | 1.2B | – | 1.3B | 1.3B | 1.3B | 1.4B | 1.2B | 1.2B | 1.2B | – | 1.1B |
| Orthopaedics and Spine | – | – | – | – | – | – | – | – | – | – | 2.1B | 2.0B | 2.1B | 2.1B | 1.9B | 1.9B | 1.9B | 1.9B | 2.1B | 1.8B | 1.9B | 1.8B | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Neurotechnology and Spine | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 820.0M | 546.0M | 744.0M | – | 773.0M | 776.0M | 739.0M | 700.0M | 628.0M | 639.0M | 598.0M | – | 538.0M |